- Home
- EVAX vs VVOS Comparison
EVAX vs VVOS Comparison
Compare EVAX & VVOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- VVOS
- Stock Information
- Founded
- EVAX 2008
- VVOS 2016
- Country
- EVAX Denmark
- VVOS United States
- Employees
- EVAX N/A
- VVOS N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- VVOS Medical Specialities
- Sector
- EVAX Health Care
- VVOS Health Care
- Exchange
- EVAX Nasdaq
- VVOS Nasdaq
- Market Cap
- EVAX 16.3M
- VVOS 18.5M
- IPO Year
- EVAX 2021
- VVOS 2020
- Fundamental
- Price
- EVAX $1.49
- VVOS $2.52
- Analyst Decision
- EVAX Strong Buy
- VVOS Strong Buy
- Analyst Count
- EVAX 2
- VVOS 2
- Target Price
- EVAX $10.00
- VVOS $6.10
- AVG Volume (30 Days)
- EVAX 76.2K
- VVOS 96.5K
- Earning Date
- EVAX 05-27-2025
- VVOS 05-13-2025
- Dividend Yield
- EVAX N/A
- VVOS N/A
- EPS Growth
- EVAX N/A
- VVOS N/A
- EPS
- EVAX N/A
- VVOS N/A
- Revenue
- EVAX $3,344,000.00
- VVOS $15,031,000.00
- Revenue This Year
- EVAX $102.45
- VVOS $23.17
- Revenue Next Year
- EVAX $100.30
- VVOS $25.23
- P/E Ratio
- EVAX N/A
- VVOS N/A
- Revenue Growth
- EVAX 4480.82
- VVOS 8.91
- 52 Week Low
- EVAX $1.20
- VVOS $1.91
- 52 Week High
- EVAX $21.80
- VVOS $6.28
- Technical
- Relative Strength Index (RSI)
- EVAX 43.19
- VVOS 45.31
- Support Level
- EVAX $1.20
- VVOS $1.98
- Resistance Level
- EVAX $1.46
- VVOS $2.33
- Average True Range (ATR)
- EVAX 0.13
- VVOS 0.25
- MACD
- EVAX 0.03
- VVOS 0.03
- Stochastic Oscillator
- EVAX 59.18
- VVOS 80.60
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About VVOS Vivos Therapeutics Inc.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.